Yaxiong Zhang

Yaxiong Zhang

Auto-generated profile, based on publicly available information

Yaxiong Zhang

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LPLanlan Pang
Lanlan Pang
YHYihua Huang
Yihua Huang
WZWeitao Zhuang
Weitao Zhuang
YZYaxiong Zhang
Yaxiong Zhang
JLJun Liao
Jun Liao
WFWenfeng Fang
Wenfeng Fang
Purpose: The current National Comprehensive Cancer Network (NCCN) guidelines recommend afatinib or osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC harboring EGFR p.G719X mutation. However, in the absence of head-to-head trials comparing afatinib with osimertinib in EGFR p.G719X-mutant patients, it is unclear which regimen is the preferred treatment option. Experimental Design: A large cohort of 4,228 treatment-naïve patients with lung cancer who underwent targeted next-generation sequencing (NGS) testing was screened for EGFR p.G719X mutation. A multicenter cohort involving 68 EGFR p.G719X-mutant patients with advanced NSCLC and NGS profiling was retrospectively enrolled to evaluate clinical responses to afatinib (n = 37) and the third-generation EGFR-TKIs (n = 31). Ba/F3 cells stably expressing the EGFR p.G719A mutation were created to investigate the response to EGFR-TKIs in vitro. Results: Concurrent EGFR p.E709X mutations, being the most frequent co-occurring EGFR mutation in EGFR p.G719X-mutant NSCLC (∼30%), exerted a detrimental effect on outcomes in patients treated with third-generation EGFR-TKI [G719X/E709X vs. G719X; objective response rate (ORR): 0.00% vs. 47.62%, P < 0.001; mPFS: 7.18 vs. 14.2 months, P = 0.04, respectively]. Conversely, no significant difference was found in the treatment efficacy of afatinib between EGFR p.G719X/E709X and EGFR p.G719X patients (G719X/E709X vs. G719X; ORR: 71.43% vs. 56.67%, P = 0.99; mPFS: 14.7 vs. 15.8 months, P = 0.69, respectively). In vitro experiments elucidated a resistant drug sensitivity and poor inhibition of EGFR phosphorylation in Ba/F3 cells expressing EGFR p.G719A/E709K mutation upon the third-generation EGFR-TKI treatment. Conclusions: Co-occurring EGFR p.E709X mutation mediated primary resistance to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients but remained sensitive to afatinib. A personalized treatment strategy should be undertaken based on the coexisting EGFR p.E709X mutation status.

14 June 2024
Verified
Other
Open access
PDF file
LPLanlan Pang
Lanlan Pang
YHYihua Huang
Yihua Huang
WZWeitao Zhuang
Weitao Zhuang
YZYaxiong Zhang
Yaxiong Zhang
JLJun Liao
Jun Liao
WFWenfeng Fang
Wenfeng Fang
Supplementary Table 3. List of genes included in the Mygene Diagnostics NGS panel. (Ion AmpliSeq Colon and Lung Cancer Research Panel v2 and Ion AmpliSeq RNA Fusion gene list)

14 June 2024
Verified
Other
Open access
PDF file
LPLanlan Pang
Lanlan Pang
YHYihua Huang
Yihua Huang
WZWeitao Zhuang
Weitao Zhuang
YZYaxiong Zhang
Yaxiong Zhang
JLJun Liao
Jun Liao
WFWenfeng Fang
Wenfeng Fang
Supplementary Figure 3. Genomic characteristics was found between patients receiving afatinib or the third-generation EGFR-TKIs.

14 June 2024
Verified
Other
Open access
PDF file
LPLanlan Pang
Lanlan Pang
YHYihua Huang
Yihua Huang
WZWeitao Zhuang
Weitao Zhuang
YZYaxiong Zhang
Yaxiong Zhang
JLJun Liao
Jun Liao
WFWenfeng Fang
Wenfeng Fang
Supplementary Table 2. Baseline characteristics of treatment-naive patients diagnosed with NSCLC who harbored EGFR G719X mutation in SYSUCC cohort (n=48)

14 June 2024
Verified
Other
Open access
PDF file
LPLanlan Pang
Lanlan Pang
YHYihua Huang
Yihua Huang
WZWeitao Zhuang
Weitao Zhuang
YZYaxiong Zhang
Yaxiong Zhang
JLJun Liao
Jun Liao
WFWenfeng Fang
Wenfeng Fang
Supplementary Figure 3. Genomic characteristics was found between patients receiving afatinib or the third-generation EGFR-TKIs.